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  The Influence of Differing Characteristics upon the Potential for a Reversal from a State 
of Impaired Glucose Tolerance to One of Normal Glucose Tolerance  
 
By: 
Rose Benedicte Gregoire 
10 August 2021 
 
Introduction: Diabetes is one of the leading causes of both morbidity and mortality 
worldwide and is a pressing concern since these figures are on the rise.  The International 
Diabetes Federation indicated that approximately 463 million adults currently have diabetes 
globally, with an additional 374 million individuals living in prediabetic state (IDF, 2019). 
Diabetes is also at the forefront with regard to costs in that it has risen from $245 billion in 2012 
(American Diabetes Association, 2018) to an estimated $327 billion in 2017—the latter of which 
is comprised of $237 billion in direct medical costs along with the remaining $90 billion incurred 
as a result of absenteeism, a reduced ability to work, and a general reduction in overall 
productivity (American Diabetes Association, 2018). While the transition from a state of 
prediabetes (i.e., impaired glucose tolerance) to overt diabetes has been heavily studied, there is a 
dearth of existing literature targeting the reversal from a state of impaired glucose tolerance 
(IGT) to one of normal glucose tolerance (NGT). Preventative measures undertaken to 
circumvent the likelihood of developing type 2 diabetes can more adeptly be accomplished by 
transitioning from a state of IGT back to a state of NGT before it is too late. Evaluating 
cardiovascular, glucoregulatory, lifestyle, and demographic characteristics along with urinary 
biomarkers, the baseline lipid profile, and anthropometric measures occurring amongst subjects 
in a state of IGT at baseline may shed light on potential predictors involved in the reversal back 
to NGT.  
Aim: The goal of this study is to evaluate the possible predictors that may incite the 
regression from a state of impaired glucose tolerance (IGT) to one of normal glucose tolerance 
(NGT). 
Methods: This study analyzed existing epidemiological data from the total insulin 
resistance atherosclerosis study (IRAS) cohort of 1,625 participants using an exploratory data 
analysis (EDA) approach. This study evaluated only participants with Impaired Glucose 
Tolerance (IGT) when measured at baseline (n=303). Subjects who transitioned from IGT to 
NGT (n=81) were compared to those who remained in a state of IGT during both visits (n=121) 
along with subjects who progressed from IGT to a state of overt type 2 diabetes at follow-up 
(n=101). Group differences for continuous and categorical variables were assessed using the 
Wilcoxon Rank Sum/Kruskal Wallis chi-square tests, respectively.  
Results: Male participants were more likely to experience a successful reversal from a 
state of IGT to one of NGT compared to their female peers. Menopausal status was a statistically 
significant characteristic serving as an impediment in the transition from a state of IGT to one of 
NGT. Subjects with elevated BMIs were significantly less likely to reverse from IGT to NGT 
compared to those with lower BMIs.  
Conclusion: The results suggest that female participants are less likely to experience a 
reversal from a state of impaired glucose tolerance to one of normal glucose tolerance compared 
to male participants. This finding appears to be contingent upon menopausal status when 
measured during both baseline and follow-up visits, respectively. 
Keywords: normal glucose tolerance, impaired glucose tolerance, type 2 diabetes, 
prediabetes reversal.  
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Prediabetes is an intermediate stage between normal glucose regulation and the onset of 
type 2 diabetes, which is problematic in that it leads to increased risks for the development of 
diabetes mellitus along with the potential onset of vascular complications [1]. More specifically, 
worldwide estimates obtained by the International Diabetes Federation indicate that while nearly 
463 million adults are currently living with diabetes, another 374 million adults are also 
prediabetic [2]. While this figure is already high, the anticipated global diabetes prevalence is 
projected to rise to 700 million by 2045 alone, which is why it is imperative that the precursors 
and biomarkers that may lead up to this are discovered and addressed.  Despite the existence of 
randomized controlled trials (RCTs) that have demonstrated relative success in preventing the 
progression from prediabetes to type 2 diabetes, they were nonetheless limited in that they 
considered lifestyle factors or pharmacological interventions only. Unfortunately, these two 
methods alone are problematic in that medications lose efficacy upon discontinuation, and 
lifestyle modification is effective solely upon the condition that it becomes an ingrained habit 
that is interwoven into the fabric of one’s daily routine.  
Moreover, while lifestyle intervention protocols have been more effective in terms of 
preventing or mitigating the progression from prediabetes to type 2 diabetes, this is not the case 
with respect to the reversal of a state of impaired glucose tolerance (IGT) back to one of normal 
glucose tolerance (NGT) instead. This poses a challenge due to the lack of extant studies that 
have deliberately focused upon the pre-specified reversal of prediabetes and the restoration of 
normal glucose regulation as a primary outcome of interest. The lack of research in this area is of 
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concern due to the emerging evidence indicating that the reversal of prediabetes to a state of 
NGT is highly important. This reversal confers benefits that include protection from the future 
development of diabetes, the minimization of complications stemming from this state, along with 
the provision of an increased likelihood of longevity during the long-term follow-up of subjects.  
Given that prediabetes is an intermediary step towards the onset of type 2 diabetes, 
understanding the complex interplay involved in the transition is necessary to tailor interventions 
to those at risk before this rare window of opportunity closes. Extant research has found that 
some of the notable predictors that are accountable for the transition from normal glucose 
regulation to prediabetes include variables such as being male, older in age, having a higher 
BMI, living with a larger waist circumference, along with having a higher conglomeration of 
total fat and abdominal adipose tissue [3, 4, 5, 6, 7, 8]. Moreover, participants with higher fasting 
plasma glucose (FPG) and two-hour plasma glucose (2hrPG) levels are also more prone towards 
the eventual onset of prediabetes; this is in accompaniment to factors such as having lower levels 
of insulin sensitivity, insulin secretion, and disposition index [5].  
Moreover, additional variables affiliated with the transition from normal glucose 
regulation to prediabetes include higher baseline plasma levels of LDL, cholesterol, and of 
triglycerides occurring in tandem with a lower level of HDL cholesterol [6, 7, 8]. The 
implication of these findings similarly resonates with respect to the reversal of prediabetes and 
the restoration of normal glucose regulation as well. More specifically, participants with lower 
baseline levels of FPG and of 2hrPG, who were younger in age, experienced greater insulin 
secretion, and who encountered weight loss were more likely to regress from a prediabetic state 
to one of NGT instead [9]. The primary body of research in this area is composed of RCTs that 
have investigated lifestyle and/or medication interventions with varying degrees of success. As a 
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result, this study goes one step further by evaluating the changes occurring over time with 
respect to measures of adiposity, the lipid profile, cardiovascular characteristics, glucoregulatory 
mechanisms, metabolites, along with anthropometric, lifestyle, and demographic characteristics 
of interest. In addition, the inclusion of F2 – Isoprostanes into this comprehensive list of factors is 
a novelty that will hopefully shed light upon that which may lead to the successful regression 
from prediabetes back to a state of NGT.1 Increasing our knowledge base on the underpinnings 
of a reversal from IGT to NGT can hopefully aid by increasing awareness, reducing the 
proliferation of diabetic comorbidities, and can hopefully save lives through a reduction of future 
risks, such as (but not limited to) cardiovascular disease (CVD) and premature mortality. 
1.2 Purpose of the Study 
The existing landscape illustrates that while a large amount of research has been 
conducted with respect to the evaluation of the progression from a state of IGT to the eventual 
onset of type 2 diabetes, there is a dearth of studies that examine the reversal of prediabetes to a 
state of normal glucose regulation. Despite the existence of several RCTs that demonstrate the 
utility behind lifestyle interventions and of pharmacological agents, they nonetheless focus 
specifically upon preventing the progression from prediabetes to type 2 diabetes [1]. As a result, 
few studies have evaluated the pre-specified reversal of prediabetes as a primary outcome of 
interest. 
While the review undertaken by Sallar and Dagogo-Jack in 2020 is the most current and 
comprehensive analysis of the existing body of research in this area [1], this study takes it one 
step further by addressing some of the incongruous findings emerging with respect to participant 
characteristics, such as demographic, adiposity, and glucoregulatory measures along with 
 
1 amongst participants in a state of IGT at baseline when followed over time for five years. 
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differences in plasma lipid and amino acid levels. As a result, the purpose of this study is to 
determine which factors (if any) are associated with the regression from prediabetes to a state of 
normal glucose tolerance (NGT) in participants when compared to those who either remained 
prediabetic or else progressed entirely to a state of diabetes when evaluated over a five-year time 
frame. 
While extant research has evaluated the impact of plasma lipid and amino acid levels 
along with glucoregulatory, adiposity, and demographic measures separately, this paper is 
novelty in that no study has fully explored the impact that these variables may have upon the 
reversal of impaired glucose tolerance (IGT) to normal glucose tolerance (NGT) when all of 
these factors are evaluated simultaneously. By accounting for as many variables as possible, this 
study attempts to investigate which ones might be associated with a regression from prediabetes 
to normal glucose regulation by using the Insulin Resistance Atherosclerosis Study (IRAS), 
which was the first epidemiologic study of its kind that was used and designed with the intention 
of analyzing relationships between insulin resistance, glycemia, insulinemia, diabetes, and 
ultimately of cardiovascular disease (CVD) within the context of a large multiethnic cohort [10]. 
In turn, the IRAS dataset provides a wealth of information through which to examine changes in 
glucose tolerance status over time due to its prospective cohort design. 
1.3 Research questions and hypotheses 
1). What is the impact of sex, ethnicity, menopausal status, and age in years on the reversal from 
a state of Impaired Glucose Tolerance back to one of Normal Glucose Tolerance?  
2).  What is the impact of weight, BMI, waist circumference, and waist/hip ratio on the reversal 
from a state of IGT back to one of NGT?  
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3.) What is the impact of Fasting Insulin, 2-Hr Insulin, Insulin Sensitivity, AIR, Fasting Glucose, 
2-Hr Glucose, and Glucose Effectiveness on the potential for reversal from a state of IGT to one 
of NGT? 
4.) What is the impact of Total Cholesterol, LDL, HDL, and Triglyceride levels, along with each 
specific F2-Isoprostane/BMI ratio on the potential for reversal from a state of IGT to one of 
NGT? 
5.) What is the impact of Hypertension, the Ankle/Brachial Index, Systolic BP, Diastolic BP, 
Mean CCA, and Mean ICA on the potential for reversal from a state of IGT to one of NGT? 
6.) What is the impact of Smoking Status, Total Energy Expended, High Energy Expended, and 
Moderate Energy Expended on the potential for reversal from a state of IGT to one of NGT? 
7.) What is the impact of urine creatinine and urine albumin on the potential for reversal from a 
state of IGT to one of NGT?  
1.4 Thesis Organization 
This thesis is organized into five chapters. Chapter I consists of an introduction of the 
issue accompanied by relevant background information, the purpose of the study, and 
subsequently includes the research questions and their respective hypotheses. The literature 
review is presented in Chapter II. The methods utilized, a description of the sample used, and the 
measures of interest are all described in Chapter III. Chapter IV is composed of the findings and 
outcomes associated with the study. Lastly, Chapter V consists of the discussion, a description of 





Chapter II:  Literature Review 
2.1 The Relationship between Glucose Homeostasis and the Progression of Diabetes 
Diabetes is one of the leading causes of both mortality and morbidity worldwide, 
accompanied by cancer, heart disease and stroke. In the United States alone, 34.2 million 
Americans live with diabetes with another 88 million who are prediabetic, which attests to the 
enormity of this ever-increasing problem [11]. Diabetes also is at the forefront with regard to 
expenses in that by 2017, the costs associated with diabetes had steadily increased to an 
estimated $327 billion. While this figure is primarily composed of $237 billion in direct medical 
costs alone, the remaining $90 billion arose as a function of absenteeism, a lessened ability to 
work, along with a general reduction in overall productivity [12]. Diabetes is also a pressing 
concern worldwide; the International Diabetes Federation (IDF) illustrated that approximately 
463 million adults currently have diabetes, with an additional 374 million individuals living in a 
prediabetic state as of 2019 alone [2]. 
These figures are on the rise; projections from the International Diabetes Federation 
anticipate that the global diabetes prevalence is expected to increase to approximately 700 
million by 2045 [2]. Prospective studies indicate that risk factors associated with the onset of 
type 2 diabetes include a propensity towards being overweight/obese accompanied by a lack of 
physical activity [13, 14, 15]. These findings illustrate the extent to which a low level of physical 
activity—when in conjunction with obesity-- is associated with impaired glucose tolerance and 
the eventual onset of type 2 diabetes [15]. Additional research by Hu et. al in 2004 further 
underscores this link in that researchers concluded that exercise and type 2 diabetes are inversely 
associated [16]. More specifically, subjects with impaired glucose regulation experienced a 
nearly five-fold increase in the acquisition of diabetes when compared to participants with 
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normal glucose levels [16]. To combat the dangers associated with the onset of diabetes mellitus, 
researchers encourage lifestyle changes (such as alterations made with respect to diet and 
physical activity) as one approach through which to mitigate potential risk factors associated 
with disease progression [17]. 
While much attention is paid to the role of insulin, the onset of type 2 diabetes arises in 
part due to IGT, which is a disturbance in normal glucose homeostasis that subsequently leads to 
abnormal glucose regulation. This abnormality is a metabolic disruption that may enable the 
inception of intermediates-- IGT and impaired fasting glucose (IFG)--which may in turn lead to 
the eventual development of diabetes [18]. NGT is comprised of both fasting and 2-hour glucose 
concentrations (<140 mg/dl) [13]. IGT is defined as the presence of an elevated 2-hour plasma 
glucose concentration (>=140 and <200mg/dl) measured after the ingestion of a 75-gram glucose 
load during an oral glucose tolerance test (OGTT) when accompanied by a fasting plasma 
glucose concentration of <126mg/dl [13].  
2.2 The Relationship between Glucose Effectiveness, Normal Glucose Tolerance (NGT), 
Impaired Glucose Tolerance (IGT), and Diabetes 
 
Researchers studying glucose tolerance amongst 827 subjects (out of the initial 1625) 
within Insulin Resistance Atherosclerosis Study (IRAS) found a notable trend in that they 
discovered that glucose effectiveness, basal insulin effect (BIE), and glucose effectiveness at 
zero insulin (GEZI) all deteriorated synchronously with worsening glucose tolerance [19]. This 
suggests that subjects with NGT at baseline experienced a decline with respect to BIE, GEZI, 
and overall glucose effectiveness (SG) when their status transitioned to either a state of IGT or 
else to one of full-blown diabetes [19]. Amongst those with NGT at baseline, the respective 
transition to either IGT or else to diabetes was in turn related to declines in SG (P<0.001), BIE 
(P=0.009) and GEZI (P<0.001) [19]. This differed starkly in comparison to the findings obtained 
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for subjects with IGT at baseline in that longitudinal changes in terms of glucose tolerance status 
led to only mildly significant changes with respect to SG (P=0.049) and BIE (P=0.042), whereas 
there was no statistically significant change in GEZI (P=0.332). These findings show that despite 
subjects reaping the benefits associated with being in a state of NGT, they may nonetheless 
experience declines in SG and in GEZI, which accompany a deterioration in glycemic status. 
However, this is diametrically opposed to that which occurs amongst those who are prediabetic 
(IGT) given that they encounter only modest changes in SG and in GEZI. The only exception to 
this occurs with respect to BIE, which worsens at all stages of glucose tolerance.  
Consequently, these findings illustrate that while glucose effectiveness (SG) is an 
important determinant of glucose metabolism [20], it also serves as a predictor of the 
development towards (and the eventual onset) of diabetes [21, 22]. Findings emerging from other 
studies indicate that SG is reduced amongst those found to be in either a state of IGT or else who 
are categorized as being diabetic [22, 23]. This suggests that unlike those who are in a state of 
NGT, glucose effectiveness may be hard to differentiate in some cases in that it appears to be 
similar amongst those with IGT and diabetes [23]. 
2.3 Biomarkers that underlie the Regression from a Prediabetic State to One of Normal 
Glucose Regulation 
 
While the transition from prediabetes to type 2 diabetes (T2D) has been intensively and 
abundantly studied, there is a lack of existing research pertaining to the regression from a state of 
IGT to one of normal glucose regulation. A review published in 2020 indicated that an increased 
focus should be placed upon the restoration of normal glucose regulation by reversing 
prediabetes through long-term follow-up and care [1]. Doing so may in turn mitigate future 
mortality and morbidity rates by reducing not only the complications emerging from diabetes but 
also by minimizing the risk of dying prematurely [1]. This newly published review from 2020 
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delves into the biomarkers that underlie the transition from NGT (or normoglycemia) to IGT and 
that potentially result from changes in factors such as (but not limited to) inflammation, 
increased adiposity, metabolomics, and glucoregulatory mechanisms [1].  Due to a wealth of 
extant research investigating the transition from a state of normal glucose regulation to either 
prediabetes and/or the onset of type 2 diabetes, results indicate that weight gain, deficits in 
insulin sensitivity, and alterations in pancreatic beta cell function are largely responsible for the 
rapid progression occurring between states of glucose tolerance and of their eventual 
deterioration over time.2 Moreover, when accompanied by biological changes to incretin 
response that occur alongside changes in inflammatory cytokines and fluctuations in hepatic 
glucose production, these events happening in unison shed even more light upon the mechanisms 
that may be responsible for declines in health over time [24, 25].  
Oxidative stress arises as a result of Reactive Oxygen Species (ROS), which are particles 
comprised of highly reactive groups of oxygen-containing molecules. More specifically, these 
molecules are produced during normal metabolic processes taking place amongst aerobic 
organisms, although the most notable occurrences in which they are generated happen in the 
mitochondria through reduction-oxidation reactions [27]. ROS induce damage through their 
ability to alter both the structural and functional properties of target molecules due to the manner 
in which they react with nucleic acids, proteins, and lipids [26]. ROS-induced oxidative damage 
in cells is avoidable when antioxidant defense mechanisms are working properly; a state of redox 
homeostasis is upheld when both the ROS levels and the antioxidant defenses are in balance 
[31]. However, this state of redox homeostasis is dismantled when there is an insufficient 
antioxidant defense system, which subsequently generates oxidative stress within the body. One 
 
2 Along with their eventual deterioration over time. 
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method used to measure an individual’s oxidative status is through the utilization and 
measurement of biomarkers such as F2-isoprostanes [27]. Polyunsaturated fatty acids easily react 
with reactive oxygen species, which in turn produce oxidation products (such as F2-isoprostanes) 
that can be easily measured. F2-isoprostanes can serve as a powerful tool with respect to 
quantification [27, 28]. The stability of these molecules enables researchers to both capture and 
in turn accurately reflect the full extent of the damage —the oxidative injury—occurring in vivo 
[30]. F2-Isoprostanes play a critical role in that their elevated levels commonly serve as an 
indication of the occurrence of oxidative stress [27, 30]. Despite this, another interpretation is 
that these heightened levels may instead reflect the level of functioning with respect to the 
mitochondrial metabolism instead; some prospective studies have demonstrated that certain 
individuals with higher F2-isoprostane levels nonetheless have a lower risk of diabetes and of 
weight gain [29, 31]. In the latter scenario, this relationship can potentially serve as a protective 
factor for individuals who are at risk of either developing IGT and/or of acquiring diabetes. More 
specifically, the isomer with the highest inverse association for those at risk of IGT and/or of 
type 2 diabetes is the 2,3-dinor-iPF2 α -III(F2-isoP) in that its protective effects also appear to be 
amplified even amongst those who are obese [29].  Due to the importance of F2-isoprostanes, 
their inclusion into this study can help to define the role that they may have (if any) with respect 
to IGT, along with the extent to which they may be involved in the reversal from a state of IGT 
back to one of NGT. 
2.4 The Reversal of Prediabetes and Subsequent Restoration of Normal Glucose Regulation 
While the bulk of extant research predominately focuses upon the transition from IGT to 
the onset of diabetes, the regression from prediabetes to a state of normal glucose regulation is of 
critical importance and should no longer be overlooked. It is preferable to reverse an individual’s 
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condition from a state of prediabetes back to one of normal glucose regulation (NGR) since 
doing so can substantially lower the risk of acquiring T2D. A shift from IGT to NGT is 
accompanied by the minimization of future diabetes-related complications [1], which attests to 
the importance of addressing these health concerns early prior to the commencement and the 
eventual manifestation of symptoms. Nonetheless, several landmark RCTs have illustrated the 
importance of lifestyle modification interventions3 with regard to health outcomes; researchers 
involved in the Malmö study found that after six years of follow up, 52% of subjects with IGT in 
the intervention group had successfully reverted back to a state of NGT [32]. This reversion to a 
state of normal glucose tolerance was complemented by modifications made in terms of blood 
pressure and hyperinsulinemia. This transition similarly led to improvements in the lipid profiles 
of the participants and was also accompanied by an amelioration in their overall acute insulin 
secretory responses to glucose [32]. 
A second study known as the Diabetes Prevention Program (DPP) similarly demonstrated 
a successful reversal from a state of IGT back to one of NGT amongst participants who were 
exposed to a lifestyle-based intervention; over 40% of subjects randomized to the lifestyle 
intervention group successfully regressed back to a state of NGT—a feat that is double the rate 
of reversal amongst those who were either exposed to the Metformin arm (20%) [9, 33] or else to 
the placebo [9, 33] instead. The two aforementioned studies indicated that subjects with a lower 
baseline fasting plasma glucose (FPG) and a reduced two-hour plasma glucose (2hrPG) when 
measured during an oral glucose tolerance test (OGTT) were more likely to successfully regress 
from a state of prediabetes back to one of NGT.  Additionally, participants who engaged in 
sustained weight loss, who incurred greater insulin secretion, and who were younger in age were 
 
3 When compared to subjects in the placebo group. 
22 
 
significantly more likely to experience a reversal from prediabetes to a state of NGR in 
approximately 40% of participants, which is an important finding [9, 33]. Overall, both the DPP 
and the Malmö study demonstrate the value and the benefits associated with the lifestyle-based 
intervention due to the manner in which a regression from prediabetes to a state of NGR was 
achieved amongst 40% to 50% of participants [9, 33]. Additional RCTs attempted to evaluate the 
influence of pharmacological agents in order to determine their effectiveness in terms of 
initiating the regression from a state of IGT to one of NGT amongst participants when measured 
either independently or else in conjunction with a lifestyle intervention. One trial involving 
randomization to either Acarbose (or else to a placebo) yielded promising initial results in that 
over 35% of participants with IGT had successfully reverted to a state of NGT after a three-year 
follow-up period.  
Despite this, the initially successful regression back to NGT was not sustained in that 
many participants unfortunately experienced a glycemic rebound after a mere three months [34]. 
Two additional RCTs investigated the influence of pharmacological agents within participants by 
testing the effects of Orlistat and Rosiglitazone in order to determine their effectiveness with 
respect to the initiation of a reversal from a state of IGT to one of NGT. Despite encountering 
initial success with around 48% of subjects having converted from a state of IGT to one of NGT, 
this gradually dwindled and is likely a testament to a waning in drug efficacy over time [35, 36, 
37]. However, the sustained reversal from a state of IGT to one of NGT amongst the participants 
who did change their routine health habits and exercise behaviors serves as a testimony to the 
importance of lifestyle modifications [37, 38, 39, 40]. This finding contrasts against the results 
found for subjects placed on medication alone due to the manner in which their regression and 
subsequent ability to remain in a state of NGT was relatively fleeting [37, 38, 39, 40]. A similar 
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result from the Malmö study that builds upon this outcome is that after twelve years of follow-
up, the participants who were successfully engaged in some form of a lifestyle modification 
experienced a mortality benefit as a result of the sustained intervention [32, 39].  
While the substantial weight loss associated with bariatric surgery has led to a greater 
likelihood of reversing 4 diabetes along with concomitant improvements made for conditions 
such as hypertension and dyslipidemia, this procedure (if undertaken on its own) is by no means 
a permanent solution [42]. Even though bariatric surgery can effectively mitigate the incidence 
of type 2 diabetes, [41] researchers in one study found that a reassessment occurring within a 
ten-year time frame (after the bariatric surgery took place) nonetheless indicated a reappearance 
of diabetes in nearly 50 percent of the patients who had previously been in remission [43]. As 
such, this finding attests to the slowly declining efficacy associated with bariatric surgery; this is 
likely due to the fact that weight loss alone may not be fully sustained unless the patients have 
fully incorporated permanent lifestyle modifications into their post-surgery routines.  
2.5 The Impact and Benefits of Regression from Prediabetes to Normal Glucose Regulation 
Attempts made to incite a reversal from a state of IGT to one of NGT is beneficial and 
cost-effective in terms of prevention since it is achievable by non-surgical means. Efforts made 
to change habits early are essential in that doing so can minimize both the risks of morbidity and 
mortality in a manner that is far less feasible to accomplish upon the onset of type 2 diabetes. 
More specifically, prediabetes (i.e., IGT) is a condition that encompasses a wide variety of 
vascular complications such as retinopathy, neuropathy, nephropathy, stroke, myocardial 
infarction, and even cardiovascular death, all of which may be mitigated with early preventative 
efforts [25]. The benefits associated with a clinical regression from a state of prediabetes to NGT 
 
4 or else an amelioration of this. 
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cannot be overstated due to the manner in which those who have successfully achieved a state of 
normal glucose regulation (NGR) at least one or more times during a longitudinal study were 
able to attain a 56% lower risk of incident type 2 diabetes. However, this was not the case 
amongst subjects who were consistently prediabetic throughout the entirety of the follow-up 
period [43]. These findings subsequently illustrate how the risk reduction for the incidence of 
diabetes appear to increase concurrently with the number of times in which a participant was 
able to successfully achieve a state of NGR; even transitory states of NGR helped to diminish an 
individual’s future risk of developing diabetes [43].  In addition to reducing the onset of type 2 
diabetes, successfully regressing back to a state of NGT similarly led to a decrease in the 
prevalence of microvascular disease-- an outcome that endured over time (which is after a 
median follow-up period of 15 years) [46]. The regression of prediabetes along with the 
restoration of normal glucose regulation (NGR) in the DPP/DPPOS cohort similarly produced a 
decreased macrovascular risk amongst participants [44]. Researchers evaluating the Whitehall 
study II cohort over time found that while the majority of subjects with HbA1c-defined 
prediabetes either remained in a state of IGT or else progressed to type 2 diabetes over a five-
year period, there was nonetheless a small subset (of the participant population) that experienced 
a successful reversal from prediabetes to a state of normoglycemia [47]. While these alterations 
may be due to random fluctuations occurring amongst certain participants, the reversion from 2h 
PG-defined prediabetes back to a state of NGT was nonetheless beneficial in that it led to a 
reduction in the risks that are associated with both the onset of heart disease and of CVD-related 
mortality [47]. 
Addressing the onset of impaired glucose tolerance is necessary due to the limited 
success associated with lifestyle interventions alone. Despite the emergence of certain benefits, 
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these interventions (when undertaken alone) may be insufficient in terms of either reversing 
prediabetes or else in delaying the onset of type 2 diabetes.  By targeting important biomarkers, 
addressing related glucoregulatory mechanisms, and evaluating alterations in adiposity, 
metabolites, and in the lipid profile, the ensuing research findings can hopefully help to shed 
light upon a host of variables responsible for inciting a reversal from a state of IGT back to one 
of NGT [1]. With a greater understanding of the predictors involved in this regression, further 
studies can hopefully aid in the creation of targeted and tailored interventions that can mitigate 




















3.1 Data Source and the Study Population  
The data source utilized for the purpose of this secondary data analysis is the Insulin 
Resistance Atherosclerosis Study (IRAS), which was a prospective cohort epidemiological study 
that was a novelty due to the manner in which it examined a wealth of risk factors and their 
subsequent associations with diabetes and insulin resistance syndrome 5[10]. The study began in 
1992 with the approval of the Institutional Review Board (IRB) of Wake Forest University 
School of Medicine [46]. The final sample consisted of a diverse population comprised of non-
Hispanic whites (n=614), African Americans (n=464), and Hispanics (n=548) to ensure 
generalizable and all-encompassing results.  
A total of 1625 participants aged between 40 to 69 years at baseline were recruited into 
this longitudinal study in the time frame spanning from October of 1992 to April 1994. The 
cohort was comprised of 719 male and 905 female participants, respectively. In order to ensure 
metabolic diversity, researchers tried to recruit an equivalent number of individuals deemed to be 
in a state of IGT, one of NGT, or else who were classified as being diabetic. Investigators 
accomplished this by oversampling nondiabetics who either exhibited an elevated fasting plasma 
glucose level or who were previously identified as being in a state of IGT. The baseline 
measurements taken indicated that the majority of subjects had a normal glucose tolerance status 
(44%), followed by a sizable portion of subjects who were either already diabetic (33%) or else 
were categorized as being in a state of IGT (23%). Subjects were enlisted from four specific 
clinical centers located in San Antonio, TX; Los Angeles, CA; San Luis Valley, CO; [and] 
 
5 to merely name a few of the ensuing conditions. 
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Oakland, CA. From 1997 to 1998, a follow-up examination was administered to the participants 
approximately five years after the initial baseline examination (mean 5.2 years [range 4.6-6.6]), 
which was accompanied by a high response rate of 81% [10]. This indicates that the majority of 
the initial cohort remained, with only 19% of subjects being lost to follow-up. Each participant 
gave his/her written informed consent, and the protocols were approved by local IRB committees 
for both the baseline and follow-up examinations [10]. 
3.2 Screening and Eligibility, the Sample Selection Process, and Variable Measurement  
The oral glucose tolerance test (OGTT) was utilized to measure baseline glucose 
tolerance amongst participants, which is in direct accordance with the standards established by 
the World Health Organization [47]. Participants underwent two separate visits to properly 
obtain all of the required baseline information. With each visit lasting for approximately four 
hours, the time interval between the two consecutive appointments spanned from one to thirty 
days. Prior to the morning of the two visits, researchers asked that participants refrain from 
alcohol consumption, avoid high intensity exercise, and that they also fast for 12 hours 
beforehand [10].  The OGTT procedure is performed by taking an initial blood sample prior to 
imbibing a liquid containing 75 grams of glucose.6 Blood was drawn again two hours after 
consuming a solution needed to measure the remaining amount of glucose found in the system of 
each respective subject. Insulin resistance was assessed by using the frequently sampled 
intravenous glucose tolerance test (FSIGT) during the first and second visits [10]. In order to 
ensure the accuracy of the insulin levels obtained amongst diabetics, subjects received an 
injection of insulin as opposed to tolbutamide. Researchers did so this to acquire adequate plasma 
insulin levels with greater ease given that some diabetics experienced either a blunted or an 
 
6 This procedure is used to measure a subject’s fasting blood glucose level. 
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absent insulin response to glucose [48]. Researchers also utilized a reduced sampling protocol by 
requiring that only 12 plasma samples be collected as opposed to the 30 that are more frequently 
used in this procedure [48]. Measuring insulin resistance was accomplished through the 
administration of both regular human insulin (0.03 U/kg) and glucose in the form of a 50 % 
solution (0.3 g/kg). These were injected every 20 minutes amongst subjects through an 
intravenous line, with researchers inoculating participants with the glucose solution first [10]. 4 
mL samples of blood were collected 12 separate times during a period of three hours through a 
second intravenous line. These twelve respective samples were subsequently assayed in order to 
measure the respective levels of plasma glucose and insulin concentrations. Participants fasted 
for a period of twelve hours prior to their blood being drawn in order to measure their lipids, 
fasting blood glucose levels, and the components of the biochemical profile more effectively.  
Subjects filled out questionnaires regarding their self-reported conditions whereas 
information pertaining to prevalent CVD and peripheral vascular disease was acquired through 
the use of electrocardiographic and ultrasonographical methods. In addition to measuring blood 
pressure, trained medical personnel evaluated subjects noninvasively in order to acquire their 
respective anthropometric measurements. Body Mass Index (BMI) was calculated based on 
weight measured in kilograms (kg) divided by height (in meters squared) for each of the 
participants at baseline. During the first visit, F2-Isoprostanes were measured in urine samples 
that were acquired and then stored at -70 degrees Celsius before being analyzed using liquid 
chromatography [49]. Although a total of 901 urine samples were initially collected, researchers 
only included 857 samples when attempting to measure the F2 – Isoprostanes concentration. The 
concentration of F2 – Isoprostanes was evaluated through the use of liquid 
chromatography/tandem mass spectrometry and the results were calibrated according to the 
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urinary concentration of creatinine. More specifically, creatinine was assayed using a fast 
electrospray ionization-tandem mass spectrometry method [49]. The inclusion of four different 
F2 – Isoprostanes isomers was deliberate in order to measure them within the context of potential 
fluctuations in BMI over time in an attempt to evaluate the influence that they may have (if any) 
upon the potential for regression from a state of IGT back to one of NGT. The F2 – Isoprostanes 
included were the following: iPF(2a)-ΙΙΙ, 2,3-dinor-iPF(2a)-ΙΙΙ, iPF(2a)-lV, along with 8,12-iso-
iPF(2a)-lV. The F2 -Isoprostanes index—the mean of the four aforementioned standardized F2-
Isoprostanes--was created based on the result for the four F2 – Isoprostanes isomers. This index 
allowed for the ranking of participants to occur based upon a specific calculation, which is as 
follows: [(X1i – M1)/SD1 +(X2i -M2)/SD2 +(X3i -M3)/SD3 +(X4i -M4)/SD4)/4]. In the context of this 
formula, “i” is a code for a participant, X1-4 represent values indicative of the four F2 – 
Isoprostanes isomers, M1-4  illustrates the mean of these four isomers, and SD1-4  stands for the 
standard deviation values.  
In order to ensure the accuracy of the results, participants were interviewed in their 
preferred language [10]. The interview component of the two visits was comprised of questions 
regarding whether or not each subject had any existing history related to previous instances of 
myocardial infarction, stroke, coronary and/or carotid artery surgery, along with whether or not 
he/she had endured peripheral vascular surgery [10]. Race/ethnicity was acquired through a self-
report manner, and nutrient intake data was both collected and assessed using a 114-item food 
frequency interview instrument adapted by the National Cancer Institute (NCI) and subsequently 
modified in order to account for both regional and ethnic food choices [50]. Information related 
to alcohol consumption—both recent and average lifetime use—was similarly acquired with 
questionnaires. Participants filled out surveys in order to obtain information regarding physical 
30 
 
activity; responses were based on a one-year activity recall to improve feasibility and to 
ultimately aid in their recollection of events [51]. In order to properly assess engagement in 
physical activity, modifications were made to questions in an attempt to enhance the 
responsiveness of subjects. This was accomplished by accounting for wide variety of activities 
undertaken either at home, while at work, or even for leisurely purposes given that there was a 
differential occurring between those living in urban environments relative to subjects residing in 
rural areas instead [10]. 
3.3 The Definitions of “IGT” and “NGT” along with Their Respective Classifications 
 
Since the purpose of this study was to evaluate those who were identified as being in a 
state of IGT at baseline, this reduced the overall sample size from 1625 to only 303 subjects. 
When measured amongst participants at baseline, IGT was defined as having a fasting glucose < 
140 mg/dL and a 2-hr glucose ≥ 140 and <200 mg/dL when using the oral glucose tolerance test 
(OGTT). In order to differentiate between the two states, those categorized as having NGT had 
both a fasting and a 2-hr glucose level < 140 mg/dL, whereas those who were diagnosed as 
diabetic instead were exhibiting fasting glucose levels of ≥ 140 mg/dL or 2-h glucose ≥ 
200mg/dL.  By evaluating participants with IGT at baseline, there were only three possible 
combinations (IGT to NGT, IGT to IGT, and IGT to T2D) from which to transition upon visit 2.7  
However, this group of 303 participants was bifurcated into only two groups (as opposed 
to the initial three combinations) upon which to make comparisons for simplicity. The first group 
contains those who successfully reversed from a state of IGT back to one of NGT (n=81), 
whereas the second group is comprised of subjects who did not successfully transition backwards 
 
7 This led to a smaller cohort of only 303 individuals.  
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to a state of NGT. By combining those who remained in a state of IGT along with participants 
who transitioned from IGT to T2D, this led to the second group being composed of 222 subjects.  
3.4 Analytical Cohort 
The analytical cohort is comprised solely of participants categorized as being in a state of 
IGT at baseline. Despite 370 participants having been initially classified as having IGT during 
visit 1, only 303 individuals were ultimately included given that 65 participants were lost to 
follow-up. Amongst the remaining 303 subjects, 81 individuals successfully reversed from a 
state of IGT to one of NGT. The majority of participants (n=222) either remained in a state of 
IGT during both visits or else had developed type 2 diabetes. 
3.5 Statistical Analysis  
This study utilizes exploratory data analysis (EDA) in the examination of the Insulin 
Resistance Atherosclerosis (IRAS) cohort—a dataset initially comprised of 1624 participants. 
The requisite analyses were performed using SAS software (version 9.4). Descriptive statistics 
were computed for the entire baseline sample of the IRAS (n=1624) prior to analyzing those who 
were classified as being in a state of IGT.8 While there were 370 individuals with IGT at 
baseline, the final sample consisted of only 303 participants due to 65 subjects being classified as 
“missing” upon follow-up.9 Evaluating statistical significance for the categorical variables across 
both groups10 was acquired using the Wald Chi-square test. However, given the small sample 
size (n=189) associated with measuring menopausal status during visits, Fisher’s exact test was 
utilized instead to account for this stipulation. 
 
8 This serves as a baseline against which to compare for those who had IGT at baseline relative 
to the entire cohort. 
9 after the requisite five-year time span had passed. 
10 those who “reversed from IGT back to NGT” vs. subjects who had “no transition to NGT.” 
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In order to properly evaluate the continuous variables, a univariate analysis was utilized 
in SAS. Basic descriptive statistics such as the mean, median, the number of missing subjects, 
and the interquartile range are provided. Tests for normality were run beforehand to ensure that 
the continuous variables of interest could be properly analyzed with the Wilcoxon rank-sum test 
along with the Kruskal-Wallis test prior to their inclusion. After passing an inspection to ensure 
normality, every continuous variable was analyzed with a Wilcoxon rank-sum in order to 
determine the presence of a significant difference (if any) that may have emerged between the 
two separate groups. Analyzing differences between these two groups both at baseline and again 
five years later (during the follow-up appointment) was accomplished. This was done in order to 
determine if there were any significant differences emerging with respect to each variable (across 
both groups) through the utilization of p-values generated in SAS. The results were found to be 
of a statistically significant nature if the resulting p-value for a variable was less than 0.05. If the 
opposite held true, then the results generated were not considered to be significantly different 
across both groups of interest.  
After making comparisons in which both the continuous and categorical variables were 
evaluated independently across both groups for visits 1 and 2, we then tabulated the difference 
occurring over time (or “delta”). The difference is equivalent to the results for visit 2 subtracted 
from the outcomes found for visit 1.  By measuring the delta and then calculating the p-value for 
each variable of interest, this can help to determine whether or not the comparison of change was 
in fact significantly different between those who transitioned from a state of IGT back to NGT 
when compared to the subjects who did not. Analyzing the difference over time for each variable 
was necessary in order to determine whether or not a statistically significant increase or decrease 
was occurring when measured between these two groups. By looking at a wide array of 
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variables, this study is a novelty due to its inclusion of as many factors as possible11 in order to 
glean insight into a sector of diabetes research that so far has received limited attention. 
For the purpose of this study, the continuous and categorical variables were organized 
into seven respective tables and grouped according to key commonalities. For instance, Table I is 
comprised of the demographic characteristics of participants with IGT at baseline and it 
encompasses age, gender, race/ethnicity, and menopausal status. Table 2 consists of the baseline 
anthropometric measures amongst participants with IGT at baseline and contains variables such 
as weight, BMI, average waist circumference, and concludes with a waist/hip ratio measurement. 
Table 3 encompasses the glucoregulatory characteristics of those with IGT at baseline, which 
ultimately consists of variables such as FPG, 2-hr glucose, glucose effectiveness, insulin 
sensitivity, AIR, fasting insulin, and 2-hr insulin. Table 4 is comprised of the baseline lipid 
profile of participants in a state of IGT at baseline; the variables consist of total cholesterol, 
triglycerides, HDL, and LDL levels, respectively. Table 5 contains the cardiovascular 
characteristics of the participants with IGT at baseline, which involve blood pressure 
measurements, variables pertaining to the carotid arteries, and the ankle/brachial index. Table 6 
accounts for the baseline lifestyle characteristics of participants with IGT during visit one, and it 
is comprised of several variables connected to variant levels of energy expenditure along 
information related to with the self-reported smoking patterns of subjects.  Lastly, table 7 
encapsulates the remaining characteristics12 which consist of urinary biomarkers (such as 
creatinine, albumin, and the four aforementioned F2-Isoprostanes). Through the incorporation of 
as many variables as possible, this study attempts to motivate future work and further analyses 
 
11 All of which are taken from the IRAS data set. 
12 that did not fall into any of the aforementioned categories. 
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within this area.13 By emphasizing the importance of prevention, expounding upon the 
characteristics involved in the reversal from IGT back to a state of NGT is essential before it is 


























4.1 Description of the Entire Study Sample 
The study population was initially comprised of the entirety of the IRAS cohort—a total 
of 1625 participants—when measured at baseline. 55.73% of subjects were female with 44.27% 
of participants identifying as male.  Non-Hispanic Whites accounted for the largest subgroup 
(37.68%), followed by Hispanics (33.74%) and Non-Hispanic Blacks (28.57%) upon further 
stratification. The cohort was primarily composed of subjects in the age range from 60 to 69 
(37.65%), followed by those aged from 50 to 59 years old (34.20%) with only 28.16% of 
subjects between 40 to 49 years of age. In terms of lifestyle habits and behaviors, most 
participants had never smoked (43.67%), with a slightly smaller percentage indicating that they 
had a former history of smoking but had since quit (39.65%). Current smokers (of which there 
were 270) accounted for the smallest group (16.68%) when assessed by self-report. With respect 
to hypertension, the majority had normal blood pressure readings (61.01%), with hypertensive 
participants being in the minority (38.99%) at baseline. In terms of overall diabetes status, 718 
participants exhibited normal glucose tolerance (NGT) levels when measured at baseline 
(44.21%). In addition to those with NGT, 537 subjects were identified as having diabetes 
(33.07%) with a subset of only 369 individuals categorized as being in a state of IGT (22.72%). 
Moreover, with 41.62% of subjects having been classified as overweight and another 37.27% 






Table 1. Categorical Variables that are Baseline Characteristics for the Entire IRAS Cohort 
Categorical Variables  N (missing values) Percent 
Gender 1624 (0) 100 
     Males 719 44.27 
     Females 905 55.73 
 Race/Ethnicity 1624 (0) 100 
     Non-Hispanic White 612 37.68 
     Non-Hispanic Black 464 28.57 
     Hispanic 548 33.74 
Diabetes Status 1624 (0) 100 
     Normal Glucose Tolerance (NGT) 718 44.21 
     Impaired Glucose Tolerance (IGT) 369 22.72 
     Diabetic 537 33.07 
Hypertension 1616 (8) 100 
      Yes (High) 630 38.99 
      No (Normal) 986 61.01 
Smoking Status 1619 (5) 100 
      Never Smoked 707 43.67 
      Former Smoker 642 39.65 
      Current Smoker 270 16.68 
Weight Categorization 1617 (7) 100 
      Normal 341 21.09 
      Overweight 673 41.62 

















Table 2. Continuous Variables that are Baseline Characteristics for the Entire IRAS Cohort 
Continuous Variables N (missing values) Mean (SD) 
Age (measured in years) 1624 (0) 55.647 (8.469) 
Fasting Glucose (mg/dl) 1623 (1)  123.269 (49.53) 
BMI (kg/m2) 1617 (7) 29.47 (5.978) 
2-hour Glucose (mg/dl) 1612 (12) 186.52 (104.567) 
Triglycerides (mg/dl) 1615 (9) 152.17 (120.33) 
Fasting Insulin (uU/ml) 1620 (4) 18.37 (15.52) 
HDL (mg/dl) 1615 (9) 45.040 (14.609) 
F2 -IsoP Index
1
 627 (997) 0.030 (0.845) 
8,12-iso-iPF(2a)-lV (ng/mg CN) 627 (997) 4.25 (2.938)  
iPF(2a)-lV (ng/mg CN) 627 (997) 6.539 (4.1265)   
2,3-dinor-iPF(2a)-ΙΙΙ (ng/mg CN) 627 (997)  4.55 (3.223)  
iPF(2a)-ΙΙΙ (ng/mg CN) 627 (997)  0.251 (0.197)  
Insulin sensitivity 
(SI, x10-4minutes-1/µUml) 
1482 (142) 1.645 (1.892) 
Acute Insulin Response 
(microU/ml) 
1560 (64) 345.358 (455.081) 
Urine Creatinine (mg/dL)  1587 (37) 133.743 (80.81) 
Urine Albumin (mg/L) 1592 (32) 22.955 (65.35) 
LDL (mg/dl) 1560 (64) 141.224 (35.216) 
AIR (mean of 2,4 min ins)  1535 (89) 53.152 (51.308) 
Total Energy Expended 
(kcal/kg/yr) for Visit I 
1596 (28) 14573.62 (2641.46) 
High Energy Expended (kcal/kg/yr) 
for Visit I 
1603 (21) 1173.07 (2381.38) 
Moderate Energy Expended 
(kcal/kg/yr) for Visit I 
1600 (24) 2642.40 (2454.00) 
Note: The Index is the mean of four standardized F2-Isoprostanes 
 
4.2 Prevalence of participants with IGT when measured at Baseline 
As shown in Table 1, 369 individuals were identified as being in a state of IGT at 
baseline (22.72%). Due to attrition occurring over the five-year time frame, only 303 of those 
with IGT at baseline remained.14 At follow-up, the participants were bifurcated into two 
respective categories, the first of which consists of those who reversed from a state of IGT to one 
 




of NGT (n=81). The second group contains subjects who remained prediabetic (i.e., IGT) during 
both visits (n=121) along with those who fully transitioned from a state of IGT to overt diabetes 
(n=101) which total to 222 when combined. 
4.3 The Characteristics of Participants with IGT at Baseline and the Potential for Reversal 
 
In table 3, sex (p=0.0438) and menopausal status (p=0.0350) were statistically 
significant, whereas this was not the case for ethnicity and age during visit 1. Amongst those 
who successfully regressed from a state of IGT back to NGT (n=81), 46.91% were male 
participants accompanied by a slightly higher composition of female subjects (53.09%).  In table 
4, subjects with a lower average waist circumference (mean of 91.70) were more likely to 
reverse from a state of IGT backwards to one of NGT; participants who failed to transition were 
more likely to have a higher average waist circumference (mean=96.07) (p=0.0061). 
Additionally, those with lower BMIs (mean=28.84) experienced a higher rate of regressing from 
a prediabetic state back to NGT relative to their peers with higher average BMIs (mean=31.10) 
(p=0.0056). Lastly, no statistically significant differences emerged across groups with respect to 
the waist/hip ratio (p=0.1324), weight (p=0.0853) and height (p=0.1003) in table 4. 
As illustrated in table 5, those with a lower fasting insulin level (mean=15.43) at baseline 
were significantly more likely to reverse from a state of IGT back to NGT when compared to 
subjects who did not (mean=20.85) (p=0.0029). Moreover, individuals with greater levels of 
insulin sensitivity (mean=1.79) were significantly more likely to regress from IGT to NGT when 
compared to those with lower levels of insulin sensitivity (mean=1.10) (p=0.0035). Participants 
with a lower amount of fasting glucose (mean=100.73) were also more likely to experience a 
successful reversal of prediabetes relative to subjects who had higher fasting glucose levels 
(mean=106.11) (p=0.0003). Those with a greater acute insulin response (AIR) (mean=478.89) 
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were more likely to reverse from IGT to NGT when compared to those with a lessened AIR 
(mean=313.79) when calculated with the mathematical minimal model (p=0.0026). Participants 
exhibiting lower levels of 2-hr glucose (mean=155.38) were also more likely to experience a 
successful reversal back to a state of NGT relative to those who had higher levels of 2-hr glucose 
(mean=106.11) (p<.0001).  
In table 6, participants exhibiting a greater HDL level (mean=48.67) were significantly 
more likely to transition backwards from a state of IGT to one of NGT when compared to those 
with a lower HDL level (mean=43.82) (p=0.0061). Subjects with higher levels of triglycerides 
(mean=163.08) were less likely to successfully return to NGT from a prediabetic state relative to 
participants with lower triglyceride levels (mean=131.52) (p<0.0001). However, other variables 
from which the baseline lipid profile is comprised did not generate significant findings between 
the two groups, such as total cholesterol (p=0.3559) and LDL levels (p=0.5428). As shown in 
table 7, there were no statistically significant links between cardiovascular characteristics and a 
subsequent transition from a state of IGT to NGT.  
As showcased in table 8, there were no statistically significant outcomes occurring 
between baseline lifestyle characteristics--the types of energy expenditure and smoking status-- 
and an eventual transition from a state of IGT to NGT. As delineated in table 9, the four F2-
Isoprostanes along with urine creatinine and urine albumin did not produce any statistically 
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• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test; Fisher’s Exact Test was used to analyze Menopausal Status due to its 
small sample size (n=189) whereas the Wald chi-square test was utilized for the remaining 
categorical variables. These are stratified above with the respective N and % provided for each of 
the levels. 
 
Table 4: Baseline Anthropometric Measures in Participants with IGT (at Visit 1) 
Participant 
Characteristics*  
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 


















96.07 (12.84)  

























Missing 0  0 
Waist/Hip Ratio  

















Weight (in Kg.) 

















Height (in cm.) 

















• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
Table 5: Glucoregulatory Characteristics of Participants with IGT at Visit 1 
Participant 
Characteristics* 
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 

























2 Hr Insulin (uU/mL) 

















Si value  





































AIR from MINMOD 






478.89 (465.01)  




313.79 (332.70)  





2 Hr Glucose (mg/dL) 







































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
Table 6: Baseline Lipid Profile of Participants with IGT (at Visit 1) 
Participant 
Characteristics* 
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 
at Follow-Up  
(N= 222) 
P-Value 
Tot Chol (mg/dL) 









































































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
Table 7: Cardiovascular Characteristics of Participants with IGT (at Visit 1) 
Participant 
Characteristics** 
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 




(At visit 1) 
High N (%) 
Normal N (%) 

































Mean Internal Carotid 
Artery Far Wall Max. 





















Carotid Artery Far 
Wall Max. 



































































Missing 0 0 
• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast. 
 *Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test; the Wald chi square test was utilized for the remaining categorical 
variables. 
Table 8: Baseline Lifestyle Characteristics of Participants with IGT (at Visit 1) 
Participant 
Characteristics* 
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 




(At visit 1) 
Never- N (%) 
Ex- N (%) 
Current- N (%) 
Missing N (%) 
 
 
38 (46.91 %) 
30 (37.04 %) 




107 (48.20 %) 
88 (39.64 %) 





























High Energy Expended 
(kcal/kg/yr) 












































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 







Table 9: Urinary Biomarkers amongst Participants at Baseline 
Participant 
Characteristics*  
Reversal from IGT to 
NGT upon Follow-Up 
(N=81)  
No Transition to NGT 

























Urine Albumin (mg/L) 














































































































































































-1.00 (19.65)  










*All continuous variables are reported with the mean, standard deviation, median, along with the 
IQR, which is the 75th-25th percentile contrast. 
**Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
4.4 Results found for Participants with IGT at Baseline when Examined during Follow-up 
In table 10, menopausal status produced a statistically significant result in which female 
subjects who either pre-menopausal (n=7, 16.28%) or else peri-menopausal (n=3, 6.98%) were 
more likely to successfully reverse from IGT back to a state of NGT (p=0.0089). Amongst those 
who did not transition backwards, 93.15% of the women in that group (n=136) identified as 
being post-menopausal upon follow up; this percentage is far higher than the 76.74% of post-
menopausal women who did successfully revert from a state of IGT (n=33) back to one of NGT. 
While this reinforces previous results found with respect to the statistically significant influence 
of gender, age did not elicit a statistically significant result (p=0.6080).  
Subjects with a lower average waist circumference (mean= 93.61) as shown in table 11 
were more likely to reverse from prediabetes to a state of NGT; those who did not had higher 
average waist circumferences (mean=98.39) overall (p=0.0031). Subjects with lower BMIs at 
follow-up (mean=29.22) were more successful in reversing from a state of IGT to one of NGT. 
In contrast, subjects with higher BMIs (mean=31.79) were less likely to successfully transition 
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backwards (p=0.0011). No statistically significant differences emerged for the waist/hip ratio 
(p=0.1081) or else for the weight variable (p=0.0562) when measured at follow-up.  
 In table 12, subjects with a lower fasting insulin (mean=18.23) were significantly more 
likely to reverse from a state of IGT back to one of NGT in comparison to those with higher 
fasting insulin measurements (mean=23.83) at follow-up (p=0.0006). Similarly, participants with 
lower 2-hr insulin levels (mean=117.45) at follow-up had more success in regressing from a 
prediabetic state back to one of NGT relative to those with higher 2-hr insulin levels 
(mean=167.62) given that the latter had far more difficulty achieving this reversal (p<0.0001). 
Additionally, individuals with greater levels of insulin sensitivity (mean=1.47) were also 
significantly more likely to reverse from a state of IGT to one of NGT in comparison to those 
with decreased insulin sensitivity (mean=0.80) overall (p<0.0001). Subjects with a lower amount 
of fasting glucose (mean=98.39) were also more likely to experience a successful reversal of 
prediabetes relative to their peers who exhibited higher fasting glucose levels (mean=121.53) at 
follow-up (p<0.0001). Participants with a greater acute insulin response (AIR) (mean=648.09) 
were more likely to reverse from a state of IGT to one of NGT in comparison to those with a 
lesser AIR (mean=263.46) during visit 2 (p<0.0001).15 In terms of 2-hr glucose, subjects with 
higher levels (mean=212.15) were less likely to transition backwards from a state of IGT to NGT 
when compared to participants who exhibited lower levels of 2-hr glucose (mean=119.76) at 
follow-up (p<0.0001).   
Table 13 indicates that the subjects with greater HDL levels (mean=50.58) were 
significantly more likely to transition from a state of IGT to one of NGT relative to those with 
lower HDL levels (mean=45.19) at follow-up (p=0.0153). Participants with higher levels of 
 
15 when calculated utilizing the mathematical minimal model. 
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triglycerides (mean=155.64) were less likely to successfully regress to NGT from a prediabetic 
state when compared to those with lower triglyceride levels (mean=116.93) (p<0.0001). The 
inclusion and analyses of the ratios of the four F2-Isoprostanes
16 did not produce any significant 
results. Moreover, no significant findings emerged for total cholesterol (p=0.0706) or for LDL 
levels (p=0.1339) when both variables were measured during the follow-up visit. 
In table 14, no statistically significant findings emerged with regard to cardiovascular 
characteristics and the potential for a reversal from prediabetes to a state of NGT. The same held 
true for lifestyle characteristics in that no statistically significant findings arose for the three 
types of energy expenditure or for smoking status (which is displayed in table 15). As shown in 
table 16, both urine creatinine (p=0.3162) and urine albumin (p=0.7782) failed to generate 
statistically significant findings with respect to regressing from a state of prediabetes back to one 
of NGT.   
Table 10. Demographic and Baseline Characteristics by Glucose Tolerance Status (at Visit 2) 
Participant 
Characteristics   
Reversal from IGT 
to NGT (N=81)  





(At visit 2) 
Pre- N (%) 
Peri- N (%) 
Post- N (%) 














Age (in years)  















*As a categorical variable, Menopausal Status required the utilization of Fisher’s Exact test 
in order for the p-value to appropriately account for the small sample size (n=189). This 
variable is stratified above with the N and % provided for each level. 
 
16when each of the F2-Isoprostanes are divided by the BMI acquired for visit 2. 
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• All continuous variables are reported with the mean, standard deviation, median, along 
with the IQR, which is the 75th-25th percentile contrast.  
 
Table 11: Anthropometric Measures in Participants with IGT (at Follow-Up) 
 
Participant 
Characteristics*   
Reversal from IGT to 
NGT (N=81)  












































Waist/Hip Ratio  


















Weight (in Kg.) 


















Height (in cm.) 






















• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon 














Reversal from IGT to 
NGT (N=81)  
No Transition to 
























2 Hr Insulin 
(uU/mL) 

















Si value  











































































2 Hr Glucose  
(mg/dL) 





















• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
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Reversal from IGT to 
NGT (N=81)  




Tot Chol (mg/dL) 
















































































Ratio of  
(iPF_2a)/BMI_2  





















Ratio of  
(ipf2_ng_mg_cn)/B
MI_2 








































































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 




Reversal from IGT 
to NGT (N=81)  




(At visit 2) 
High N (%) 
Normal N (%) 




































Far Wall Max. 























Far Wall Max. 













































































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical 
variables. The categorical variable is stratified above with the respective N and % provided for 
each level. 
 
Table 15: Lifestyle Characteristics of Participants with IGT at Follow-Up 
Participant 
Characteristics*  
Reversal from IGT 
to NGT (N=81)  
No Transition to 
NGT (N= 222) 
P-Value 
Smoking Status 
(At visit 2) 
Never- N (%) 
Ex- N (%) 
Current- N (%) 










107 (48.63 %) 
96 (43.63 %) 





































































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical 
variables. “Smoking status” is stratified above with the respective N and % provided for each 
level. 
 
Table 16: Urinary Biomarkers amongst Participants at Follow-Up 
Participant 
Characteristics** 
Reversal from IGT to 
NGT (N=81)  


























Urine Albumin (mg/L) 


















(Mean of 4 
standardized F2-














































































153.16 (100.28)  























*All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast. 
**Differences between groups for continuous variables were assessed using the Wilcoxon 
Rank Sum/Kruskal Wallis Test. 
 
4.5 The Comparison of Change in Characteristics (between visits 1 & 2) between the 
Groups of Participants who had IGT at Baseline. 
 
In table 17, menopausal status (p=0.0365) was statistically significant in terms of the 
comparison of change across both groups over time. 13.95 percent of women who reversed from 
IGT to a state of NGT were pre-menopausal both at baseline and again upon follow-up, which is 
higher relative to those who never transitioned backwards. 82.19% of women who never 
successfully reversed were post-menopausal during both visits, which is a higher percentage 
compared to the mere 67.44% of subjects who did successfully regress from IGT to NGT. 
Changes in age between the two visits bore no statistically significant impact upon the outcome 
of interest (p=0.1759). In table 18, the comparison of change between groups for BMI was 
statistically significant (p=0.0348). This indicates that participants who did not successfully 
reverse to a state of NGT had a larger increase in mean BMI over time (mean=+0.76 kg/m2) 
relative to the changes in BMI amongst subjects who did successfully transition from a state of 
IGT to NGT (mean=+0.34 kg/m2).  However, there were no statistically significant differences 




In table 19, subjects who reversed from a state of IGT to NGT experienced a decrease in 
2-hr insulin between visits 1 and 2 (mean= -15.97) whereas those who failed to transition had an 
increase in 2-hr insulin levels (mean=30.34) over time (p=0.0032). Subjects who successfully 
reversed from IGT to NGT similarly had a decrease in 2-hr glucose levels (mean= -35.81) 
whereas those who did not regress encountered higher 2-hr glucose levels (mean=45.94) over 
time (p<0.0001) A similar pattern arose with fasting glucose in that those who regressed from 
IGT to NGT had a decrease between visits 1 and 2 (mean=2.34) whereas subjects who did not 
transition backwards from IGT had an overall increase in their respective levels (mean=15.48) 
over time (p<0.0001). Participants who encountered an increase in overall acute insulin response 
(AIR) (mean=192.23) between the two visits were more likely to reverse from a state of IGT to 
NGT relative to their peers who experienced a decrease in AIR (mean= -59.52) over time17 
(p=0.0007). However, the comparison of change for fasting insulin (p=0.1291), insulin 
sensitivity (p=0.1723), and glucose effectiveness (p=0.6576) were not significantly different 
between those who transitioned from a state of IGT to NGT relative to subjects who did not. 
As shown in table 20, no statistically significant findings occurred when comparing the 
change over time for characteristics that comprise the lipid profile. In table 21, subjects who 
reversed from IGT to NGT had a lower average Common Carotid Artery18 (CCA) value 
(mean=0.00) relative to those who did not transition backwards from IGT (mean=0.05). The 
subjects who failed to regress to NGT experienced an increase in their mean CCA values over 
time between visits (p=0.0369). There were no significant findings emerging for HDL, LDL, 
total cholesterol, and triglyceride levels. Similarly, no significant differences arose with regard to 
the F2-isoprostane ratios when measured over the five-year time frame. In table 22, no 
 
17 with the mathematical minimal model. 
18 The Mean CCA is with regard to the far wall max. 
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statistically significant changes emerged for lifestyle characteristics when measured for both 
groups between visits 1 and 2. In table 23, no statistically significant changes occurred for urine 
albumin (p=0.6372) or for urine creatinine (p= 0.3887) when both biomarkers were evaluated 
over time.  
Table 17: The Change in Demographic Characteristics between Visits 1 & 2 amongst 

















Pre – Pre-N (%) 
Pre – Peri N (%) 
Pre – Post N (%) 
Peri– Peri N (%) 
Peri– Post N (%) 
Post– Peri N (%) 
Post – Post N (%) 





3 (6.98 %) 
2 (4.65%) 
0 (0.00%) 
2 (4.65%)  

















*Fisher’s Exact test was utilized for the categorical variables of interest due to the small sample 
size affiliated with menopausal status. The categorical variable is stratified above with the 
respective N and % provided for each level. 
Table  18: The Change in Anthropometric Measures between Visits 1 & 2 amongst Participants 































































































• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR, which is the 75th-25th percentile contrast.  
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
Table 19: The Change in Glucoregulatory Characteristics between Visits 1 & 2 When Measured 


































































































































• All continuous variables are reported with the mean, standard deviation, median, and IQR. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test. 
 
Table 20: The Change in the Lipid Profile Occurring between Visits 1 & 2 When Measured 











(For the comparison 
of change between 
the groups) 


































































































































































Note: The index is simply the mean of four standardized F2-isoprostanes.1  
• All continuous variables are reported with the mean, standard deviation, median, and IQR. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 









Table 21: The Change in the Cardiovascular Characteristics Occurring between Visits 1 & 2 
When Measured amongst Participants with IGT at Baseline 
 
• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 






IGT to NGT 
(N=81)  




(For the comparison of 
change between the 
groups) 
Hypertension  
High-High N (%) 
High-Normal N (%) 
Normal-High N (%) 































Mean Internal Carotid 
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Table 22: The Change in Lifestyle Characteristics occurring between Visits 1 & 2 When 












*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical 
variables. 
• All continuous variables are reported with the mean, standard deviation, median, along with 
the IQR. 
Participant 
Characteristics*   
Reversal from 
IGT to NGT 
(N=81)  
No Transition to 








Never- Never N (%) 
Never- Ex N (%) 
Ex- Never N (%) 
Ex- Ex. N (%) 
Ex- Current N (%) 
Current- Never N (%) 





































































































Table 23: The Change in the Urinary Biomarkers Occurring between Visits 1 & 2 When 
Measured amongst Participants with IGT at Baseline 
Participant 
Characteristics*  
Reversal from IGT to 
NGT (N=81)  



















































• All continuous variables are reported with the mean, standard deviation, median, and IQR. 
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank 
















5.1 Discussion of the Research Question 
 
Due to a dearth of RCTs within this specific area of diabetes research, the purpose of this 
study is to discover characteristics that may help to induce a reversal from a state of IGT back to 
one of NGT. This study takes a novel approach by using exploratory data analysis (EDA) in 
order to evaluate findings obtained from the Insulin Resistance Atherosclerosis Study (IRAS) 
cohort. In addition to the lack of extant studies examining the reversal from prediabetes to a state 
of NGT, those that are in existence focus specifically upon lifestyle and/or medication 
interventions.19 The findings generated from some of these extant studies are mixed, with 
efficacity waning over time in some instances—particularly in relation to the use of medications 
and lifestyle regimens.20 In order to acquire more information on that which may aid in the 
reversal from IGT to NGT, this study delves into several previously unexplored areas through 
the inclusion of the following: measures of adiposity, the lipid profile, cardiovascular 
characteristics, glucoregulatory mechanisms, along with anthropometric, lifestyle, and 
demographic characteristics of interest. This study goes one step further by attempting to 
understand the interplay of the potential factors that may be involved in this reversal when 
measured in simultaneity, which may help to stimulate future research studies due to the 
potential for synergistic effects.  
The first hypothesis centers upon the notion that demographic characteristics—sex, 
ethnicity, menopausal status, and age-- may serve as predictors of a reversal from a state of 
prediabetes (or IGT) back to one of NGT.  The results of this study revealed that menopausal 
 
19 These have ultimately produced varied results in terms of success. 
20 such as exercise routines.  
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status and gender 21 are statistically significant; men were more likely to reverse from IGT back 
to NGT relative to their female counterparts—an outcome that runs contrary to previous 
research. 
The second research hypothesis relating to the impact that anthropometric measures have 
upon a regression from IGT to NGT yielded mixed findings. While adults with higher BMIs 
were significantly less likely to transition from a state of IGT to NGT relative to those with 
lower BMIs, there were no significant differences across groups for the average waist 
circumference, waist/hip ratio, and weight. We conjectured that changes in glucoregulatory 
characteristics would engender a reversal from a state of IGT to one of NGT. While the study did 
find statistically significant outcomes for 2-hr insulin, AIR from MINMOD, fasting glucose, and 
2-hr glucose, this was not the case for insulin sensitivity (SI), glucose effectiveness (SG), or for 
fasting insulin. Decreases in 2-hr insulin, fasting glucose, 2-hr glucose levels, and a higher AIR 
did incite a regression from a state of IGT to one of NGT, whereas there were no statistically 
significant findings emerging across groups for changes in SI, SG, and fasting insulin when 
measured over the five-year time frame.  
We also hypothesized that changes in the lipid profile over time, which is comprised of 
total cholesterol, HDL and LDL levels, triglyceride levels, and the ratio of all four F2-
isoprostanes divided by BMI, would serve as predictors facilitating the transition from IGT back 
to an improved state of NGT. Since no statistically significant results were produced, this did not 
lend support to the findings from the current landscape of research regarding the lipid profile. 
This runs counter to the results found in the current existing literature in which lower levels of 
 
21 This comes as no surprise given that menopausal status is nested within gender and in turn 
applies only to female participants. 
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triglycerides and LDL cholesterol (when accompanied by a higher supply of HDL cholesterol) 
were found to prompt a transition from a state of prediabetes back to one of NGT.  
The fifth research hypothesis posits that cardiovascular risk factors--hypertension, the 
ankle/brachial index, systolic and diastolic measures of blood pressure, mean CCA, and the mean 
ICA--aid in the reversal from a state of prediabetes to one of NGT. However, since none of these 
variables generated statistically significant findings, this suggests that these cardiovascular 
characteristics may be inadequate predictors of a reversal from a state of IGT to one of NGT.  
The sixth research hypothesis seeks to evaluate the impact (if any) that lifestyle 
characteristics (such as energy expenditure and smoking status) have upon the potential for 
regression from a state of IGT to one of NGT. In a manner similar to cardiovascular risk factors, 
no statistically significant differences emerged with regard to lifestyle characteristics.  Smoking 
status along with the variant types of energy expenditures (which were total, moderate, and high) 
did not successfully predict the onset of a transition from a state of IGT to one of NGT.  The 
final hypothesis seeks to measure the impact of urine creatinine and urine albumin upon the 
potential for reversal from a prediabetic state back to one of NGT. Since no statistically 
significant findings arose for urinary biomarkers, this result indicates that urine albumin and 
urine creatinine were not effective predictors of a regression from a state of IGT to one of NGT.  
When testing for statistical significance, the outcomes for demographic and adiposity 
measures produced mixed results.22 The findings obtained for BMI in this study mirrors results 
that were found in the POP-ABC analysis from 201423 in that a lower BMI is an effective 
predictor in the ability to transition from IGT back to a state of NGT [1]. The reverse similarly 
held true in that in that those with higher BMIs were less likely to regress from a state of IGT to 
 
22 in terms of regressing from a state of IGT to NGT as measured in the context of this study. 
23 by Dagogo-Jack et. al. 
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one of NGT and instead were more likely to transition from IGT towards the onset of full-blown 
T2D. 
While the outcome found for BMI corroborated finding from existing research, findings 
for gender in this study ran contrary to that which is in the current background of prediabetes 
literature. This study found that men were more likely to achieve a successful regression from a 
state of IGT back to one of NGT, whereas the reverse held true for their female counterparts. 
Despite the unexpected nature of the outcome found for gender, this was supported by the 
statistically significant results found for menopausal status.24 These findings are notable in that 
they highlight a predisposition that female subjects may have given that they appeared to 
transition from a state of prediabetes (or IGT) to overt type 2 diabetes more frequently than their 
male peers. This outcome suggests that some of the underlying mechanisms relating to gender 
may not yet be fully understood. As a result, these conflicting findings merit additional research 
in order to fully address the underpinnings that at this point remain both poorly understood and 
minimally studied.   
The results acquired in this study may vary slightly in comparison to some of the findings 
from previously existing research due to several considerations. One reason for this could be due 
to the sample size being comprised of only 303 individuals. Participants met the inclusion 
criteria only if they were categorized as being in a state of IGT when measured at baseline, 
which subsequently led to a small sample size. With only 303 participants being classified as 
having IGT upon visit 1, this small n-size may in turn serve as a limitation. Another potential 
explanation that may account for the discrepancies in terms of what was deemed to be of 
 
24 When measured at baseline and again at follow-up in the context of our current study. 
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statistical significance 25 may be due to the criteria utilized and codified by researchers 
accountable for the implementation and analysis of the Insulin Resistant Atherosclerosis Study. 
The specific criteria used may influence the number of participants who were categorized as 
being in a state of IGT in addition to affecting the the number of subjects who were potentially 
discounted from being classified as prediabetic as well. The criteria used for the purpose of this 
study are based on measuring impaired glucose tolerance (IGT) using the oral glucose tolerance 
test (OGTT) along with the frequently sampled intravenous glucose tolerance test (FSIGT) [10]. 
While the OGTT and the FSIGT are commonly utilized procedures, one potential concern is that 
the results from the IRAS data set may differ from those found in other studies due to manner in 
which both IGT and NGT are operationally defined. More specifically, the operational 
definitions and criteria used can impact the overall findings by influencing the statistical 
significance of the variables chosen. Another consideration is that the decision of whether to 
accept or reject the null hypothesis may differ across studies based upon the significance levels 
and/or confidence intervals used.26 
5.2 Study Strengths and Limitations 
The prospective cohort study design exemplified by the insulin resistance atherosclerosis 
study (IRAS) is a powerful tool. It is a rare opportunity through which to evaluate changes 
occurring over time for a wide assortment of characteristics in order to find potential predictors 
that may incite a reversal from a state of IGT to one of NGT. A strength of this study is that 
analyzing the cohort from the IRAS data set allows for the observation of trends occurring over a 
five-year time frame for an entire host of factors. The extensive number of variables contained 
within the IRAS data set can ultimately set the stage for a wealth of associations between 
 
25 in addition to the variables that were deemed to not be statistically significant. 
26 Although this is rather unlikely. 
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variables to be analyzed over time in future research studies. Another strength of IRAS is that it 
is the first epidemiologic study of its kind intended to evaluate relationships between factors such 
as insulin resistance, insulinemia, glycemia, and the prevalence of cardiovascular disease (or 
CVD) when assessed in the context of a large multiethnic cohort. Moreover, researchers went to 
great lengths (and even oversampled) in an attempt to ensure as much equal representation as 
possible across all respective levels of gender, race/ethnicity, geographic region, along with the 
glucose tolerance status of participants. 
Although the criteria and the operational definitions utilized in the IRAS to measure 
glucose tolerance are widely accepted, the number of individuals who were characterized as 
having IGT at baseline was limited (n=303). As a result, this rendered a generalizable conclusion 
difficult to make and is accompanied by the inability to infer causality. Due to the unanticipated 
results arising with regard to menopausal status, it is quite possible that there may be underlying 
mechanisms or metabolic processes faced by female participants that have not yet been fully 
understood or encapsulated and that merit future research. With respect to female subjects, 
drawing conclusions regarding menopausal status and the potential for a transition in glucose 
tolerance status is difficult to make on account of the small sample size (n=189) and as a result 
the findings should be interpreted with caution. Nonetheless, the statistical methodology used in 
this study to tackle this problem—Fisher’s Exact test—does account for this exceedingly small 
sample size. This test helped to generate p-values that are more reflective of reality (despite the 
small n-size) which is another strength of this study. Lastly, the use of exploratory data analysis 
(EDA) sets the stage for future research that can build off of these preliminary results since this 




5.3 Conclusions and Recommendations 
Despite the small sample size (n=303) of the cohort used in this study, the goal is to bring 
attention to the importance of reversing prediabetes back to a state of NGT before these patients 
ultimately transition from a state of IGT to T2D and the health-related damage incurred is 
irreversible.  The contradictory nature of some of the abovementioned findings and the lack of 
statistical significance with regard to certain variables27 attest to the current paucity of studies 
and serve as a testament for why further research needs to be conducted in this area in order to 
bridge existing gaps. Novel research is needed to better understand the issues surrounding this 
inadequately studied area of prediabetes and can also help in the creation of targeted 
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